| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The compound itself has no intrinsic biological target. In bioconjugation, the sulfo-NHS ester couples to amine-containing molecules such as antibodies or proteins in aqueous buffer, while the maleimide group reacts with thiol-containing molecules such as reduced antibodies or cysteine-modified proteins. This orthogonal reactivity enables sequential attachment of two different molecules. In ADC applications, it enables conjugation of a payload to an antibody.
|
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. To specifically destroy target proteins, PROTACs take advantage of the intracellular ubiquitin-proteasome system.[1]
In vitro activity is characterized by efficient sulfo-NHS ester amine coupling at pH 7.2-8.5 for 30-60 minutes and maleimide-thiol coupling at pH 6.5-7.5 for 2-4 hours. Conjugation efficiency is assessed by HPLC or LC-MS. The sulfo group provides water solubility, eliminating the need for organic co-solvents. The C6 spacer provides flexibility between the reactive groups. |
| ln Vivo |
No direct in vivo biological activity is reported. Its utility arises from incorporation into conjugates or ADCs. The sulfo group's water solubility simplifies conjugation. The maleimide-thiol linkage is stable in plasma. In vivo studies typically evaluate antitumor efficacy of ADCs in xenograft models, with dosing via intravenous injection.
|
| Enzyme Assay |
For non-cellular binding assays, dissolve 6-Maleimidocaproic acid sulfo-NHS in aqueous buffer such as PBS at pH 7.2-8.0. Prepare amine-containing protein at 1-10 mg/mL and add linker at 5-10 fold molar excess. Incubate 30-60 minutes at room temperature. Quench with Tris-HCl at pH 8.0 to 50 mM for 30 minutes. Purify by desalting or dialysis. For maleimide coupling, reduce thiol-containing molecule with TCEP at 1-5 mM for 30 minutes, then add maleimide-functionalized protein at pH 6.5-7.5 and incubate 2-4 hours. Analyze by SDS-PAGE or LC-MS.
|
| Cell Assay |
For cell-based experiments, prepare the conjugate or ADC using the amine and thiol coupling protocols. Purify by size exclusion chromatography. Add to cultured cells at 1-100 nM in complete medium. Incubate 24-72 hours at 37 degrees Celsius. Assess cytotoxicity by MTT or CCK-8 assay if a payload is conjugated. Assess cellular uptake by flow cytometry or confocal microscopy if a fluorophore is attached.
|
| Animal Protocol |
For in vivo studies, formulate the conjugate or ADC in a suitable vehicle such as PBS or saline. Administer to mice via intravenous injection at 1-10 mg/kg every 2-3 days for 2-4 weeks in tumor xenograft models. Measure tumor volume twice weekly. Monitor body weight and clinical signs for toxicity. At study endpoint, excise tumors for immunohistochemistry and collect blood for pharmacokinetic analysis. All procedures follow IACUC-approved protocols.
|
| References |
| Molecular Formula |
C₁₄H₁₆N₂O₉S
|
|---|---|
| Molecular Weight |
388.35
|
| Exact Mass |
388.058
|
| CAS # |
103848-61-9
|
| PubChem CID |
4229288
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-0.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
26
|
| Complexity |
763
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=S(C(C1)C(N(OC(CCCCCN2C(C=CC2=O)=O)=O)C1=O)=O)(O)=O
|
| InChi Key |
NWHAVGHJSKQCHH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H16N2O9S/c17-10-5-6-11(18)15(10)7-3-1-2-4-13(20)25-16-12(19)8-9(14(16)21)26(22,23)24/h5-6,9H,1-4,7-8H2,(H,22,23,24)
|
| Chemical Name |
1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid
|
| Synonyms |
6Maleimidocaproic acid sulfoNHS; 6 Maleimidocaproic acid sulfo NHS
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5750 mL | 12.8750 mL | 25.7500 mL | |
| 5 mM | 0.5150 mL | 2.5750 mL | 5.1500 mL | |
| 10 mM | 0.2575 mL | 1.2875 mL | 2.5750 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
